1. At a Glance – The Generic Giant That Fights Patents for Breakfast
₹15,807 Cr market cap. ₹883 stock price. P/E of just 10.2. ROCE 32.8%. ROE 28%. Debt-to-equity 0.03.
Welcome to Natco Pharma Ltd, the pharma company that casually fights global Big Pharma in court, launches generics at one-tenth the price, and still posts a 30%+ EBITDA margin.
In Q3 FY26, Natco reported ₹705 Cr revenue and ₹151 Cr net profit, with EPS at ₹8.46 for the quarter. Annualised EPS (Q3 average rule applied) stands around ₹61–62, which roughly aligns with the TTM EPS of ₹86.9.
The stock is up barely 1.14% in 3 months, down 7% over one year, while the business quietly compounds profits at 33% CAGR over five years.
Industry P/E? 28.3
Natco P/E? 10.2
Either the market knows something… or it’s asleep.
Let’s investigate.
2. Introduction – The Company That Sues First and Manufactures Later
If pharma companies were Bollywood characters, Natco would be that courtroom lawyer who says:
“Objection, Your Honour… and also, we’ve already filed a Para IV.”
Natco isn’t your vanilla generic player. This is a Para IV specialist – meaning they challenge patents in the US and try to launch first-to-file generics. High risk, high reward.
And sometimes high drama.
From Risdiplam litigation victories, to Semaglutide generic approval, to acquiring 35.75% of Adcock Ingram in South Africa, this isn’t a sleepy pharma midcap.
But here’s the twist.
Despite:
- 30%+ margins
- Strong ROCE
- Near-zero debt
- Strong US pipeline
The market gives it a P/E of 10.
Is this pessimism about US pricing pressure? Patent cliffs? One-product dependency?
Or is it simply because pharma investors have PTSD from past USFDA surprises?
Let’s break it down.
3. Business Model – WTF Do They Even Do?
Natco has five segments:
1. Export Formulations (44% in Q3 FY25)
This is the US-facing business. Para IV filings. First-to-file generics. Patent challenges. Settlement agreements.
High reward. High volatility.
They’ve filed 28 Para IVs, 13 already tentatively/finally approved. That’s serious firepower.
2. Domestic Formulations (15%)
Oncology-focused branded generics in India. 850+ sales team. 1,000 distributors. Oncology is sticky and premium.
3. APIs (10%)
50+ oncology APIs. 58 DMFs filed (49 active). Vertical integration advantage.
4. Crop Health Sciences (2%)
Agrochemicals. Planning ₹130–140 Cr revenue in FY26 with break-even target.
Yes, pharma company selling pesticides. Why not?
5. Other / Contract Manufacturing (29%)
40+ pharma products for Indian majors. Tablets, capsules, injectables.
So essentially:
They:
- Fight patents
- Manufacture complex generics
- Sell oncology drugs
- Make APIs
- Export to 50+ countries
- Invest in biotech startups
- Own
